

February 3, 2023

Via Email to: AGO.highcostprescriptiondrugs@vermont.gov

Subject: Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs)

To: The Vermont Attorney General's Office

On behalf of Stemline Therapeutics, Inc. please accept this notification for the following new prescription drug Orserdu (elacestrant) introduced to the market on 02/03/2023.

NDC Number	Product Description	Date of Commercial Availability of Product	WAC/Package
72187-0101-03	Orserdu (elacestrant) Oral Tablet 86 MG, 30 count	02/03/2023	\$7,123.0
72187-0102-03	Orserdu (elacestrant) Oral Tablet 345 MG, 30 count	02/03/2023	\$21,369.00

Should there be any questions or if additional information is needed, please contact Kaltrina Berisha, Sr. Director Pricing and Contracting, at kberisha@stemline.com.